Summary
Global Markets Direct’s, ‘Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline Review, H1 2016’, provides an overview of the Clostridium difficile Infections (Clostridium difficile Associated Disease) pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Clostridium difficile Infections (Clostridium difficile Associated Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Clostridium difficile Infections (Clostridium difficile Associated Disease) and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape of Clostridium difficile Infections (Clostridium difficile Associated Disease)
- The report reviews pipeline therapeutics for Clostridium difficile Infections (Clostridium difficile Associated Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Clostridium difficile Infections (Clostridium difficile Associated Disease) therapeutics and enlists all their major and minor projects
- The report assesses Clostridium difficile Infections (Clostridium difficile Associated Disease) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Clostridium difficile Infections (Clostridium difficile Associated Disease)
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Clostridium difficile Infections (Clostridium difficile Associated Disease)
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Clostridium difficile Infections (Clostridium difficile Associated Disease) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Companies Mentioned
Absynth Biologics Limited
Actelion Ltd
Adenium Biotech ApS
AIMM Therapeutics B.V.
AmpliPhi Biosciences Corporation
Angothera GmbH
Appili Therapeutics
Assembly Biosciences, Inc.
AvidBiotics Corp.
C3 Jian, Inc
Da Volterra
Daiichi Sankyo Company, Limited
e-Therapeutics Plc
Evec, Inc.
GangaGen Inc.
ImmunoBiology Limited
Immuron Limited
Inovio Pharmaceuticals, Inc.
Integrated BioTherapeutics, Inc.
MedImmune, LLC
Merck & Co., Inc.
MGB Biopharma Limited
Microbiotix, Inc.
Micropharm Limited
Morphochem AG
Nanotherapeutics, Inc.
Novabiotics Limited
NovoBiotic Pharmaceuticals, LLC
Oragenics, Inc.
Otsuka Holdings Co., Ltd.
Pfizer Inc.
Procarta Biosystems Limited
Prokarium Limited
Rebiotix Inc.
Sanofi Pasteur SA
Seres Therapeutics, Inc.
Shire Plc
Sorrento Therapeutics, Inc.
Stellar Biotechnologies, Inc.
Summit Therapeutics Plc
Synthetic Biologics, Inc.
Valevia UK Limited
Valneva SE
VaxInnate Corporation
'
Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Clostridium difficile Infections (Clostridium difficile Associated Disease) Overview 10
Therapeutics Development 11
Pipeline Products for Clostridium difficile Infections (Clostridium difficile Associated Disease) - Overview 11
Pipeline Products for Clostridium difficile Infections (Clostridium difficile Associated Disease) - Comparative Analysis 12
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Therapeutics under Development by Companies 13
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Therapeutics under Investigation by Universities/Institutes 16
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline Products Glance 17
Late Stage Products 17
Clinical Stage Products 18
Early Stage Products 19
Unknown Stage Products 20
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Products under Development by Companies 21
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Products under Investigation by Universities/Institutes 25
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Companies Involved in Therapeutics Development 26
Absynth Biologics Limited 26
Actelion Ltd 27
Adenium Biotech ApS 28
AIMM Therapeutics B.V. 29
AmpliPhi Biosciences Corporation 30
Angothera GmbH 31
Appili Therapeutics 32
Assembly Biosciences, Inc. 33
AvidBiotics Corp. 34
C3 Jian, Inc 35
Da Volterra 36
Daiichi Sankyo Company, Limited 37
e-Therapeutics Plc 38
Evec, Inc. 39
GangaGen Inc. 40
ImmunoBiology Limited 41
Immuron Limited 42
Inovio Pharmaceuticals, Inc. 43
Integrated BioTherapeutics, Inc. 44
MedImmune, LLC 45
Merck & Co., Inc. 46
MGB Biopharma Limited 47
Microbiotix, Inc. 48
Micropharm Limited 49
Morphochem AG 50
Nanotherapeutics, Inc. 51
Novabiotics Limited 52
NovoBiotic Pharmaceuticals, LLC 53
Oragenics, Inc. 54
Otsuka Holdings Co., Ltd. 55
Pfizer Inc. 56
Procarta Biosystems Limited 57
Prokarium Limited 58
Rebiotix Inc. 59
Sanofi Pasteur SA 60
Seres Therapeutics, Inc. 61
Shire Plc 62
Sorrento Therapeutics, Inc. 63
Stellar Biotechnologies, Inc. 64
Summit Therapeutics Plc 65
Synthetic Biologics, Inc. 66
Valevia UK Limited 67
Valneva SE 68
VaxInnate Corporation 69
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Therapeutics Assessment 70
Assessment by Monotherapy Products 70
Assessment by Combination Products 71
Assessment by Target 72
Assessment by Mechanism of Action 74
Assessment by Route of Administration 76
Assessment by Molecule Type 78
Drug Profiles 80
(actoxumab + bezlotoxumab) - Drug Profile 80
(miconazole nitrate + nisin) - Drug Profile 81
ABCD-01 - Drug Profile 82
ABM-101 - Drug Profile 84
actoxumab - Drug Profile 85
Antibodies for Enterocolitis - Drug Profile 86
Antibodies to Inhibit CD Toxin A and Toxin B for Clostridium difficile Infections - Drug Profile 87
AP-114 - Drug Profile 88
ATI-1501 - Drug Profile 89
ATx-401 - Drug Profile 90
AvR2-V10 - Drug Profile 91
bezlotoxumab - Drug Profile 93
Biologic for Clostridium difficile Infection - Drug Profile 95
Biologic for Clostridium difficile Infections - Drug Profile 96
C-3CD17 - Drug Profile 97
cadazolid - Drug Profile 98
Cdiff snare - Drug Profile 99
Clostridium difficile vaccine - Drug Profile 100
Clostridium difficile vaccine - Drug Profile 101
Clostridium difficile vaccine - Drug Profile 102
Clostridium difficile vaccine - Drug Profile 103
Clostridium difficile vaccine - Drug Profile 104
clostridium difficile vaccine - Drug Profile 105
Clostridium difficile vaccine - Drug Profile 106
Clostridium difficile vaccine - Drug Profile 107
Clostridium difficile vaccine - Drug Profile 108
Clostridium difficile vaccine - Drug Profile 109
CRS-3123 - Drug Profile 110
DAV-132 - Drug Profile 111
Drugs for Clostridium difficile Infection - Drug Profile 113
DS-2969 - Drug Profile 114
EV-029104 - Drug Profile 115
EV-029105A - Drug Profile 116
fidaxomicin - Drug Profile 117
IMM-529 - Drug Profile 121
INS-001 - Drug Profile 122
INS-5010 - Drug Profile 123
INX-201 - Drug Profile 124
MBX-500 - Drug Profile 125
MCB-3681 - Drug Profile 127
MGBBP-3 - Drug Profile 128
Monoclonal Antibodies for Clostridium difficile - Drug Profile 131
Monoclonal Antibodies to Inhibit TcdA and TcdB for Clostridium Difficile and Staphylococcus Aureus Infections - Drug Profile 132
Monoclonal Antibody for Clostridium Difficile Infections - Drug Profile 133
Monoclonal Antibody to Inhibit Clostridium difficile Toxin A and Toxin B for Clostridium Difficile Infections - Drug Profile 134
NP-432 - Drug Profile 135
OG-253 - Drug Profile 136
OPS-2071 - Drug Profile 138
OraCAb - Drug Profile 139
P-100031 - Drug Profile 140
P-4A - Drug Profile 141
PF-06425090 - Drug Profile 142
PolyCAb - Drug Profile 143
PRO-391 - Drug Profile 144
ramoplanin - Drug Profile 145
RBX-2660 - Drug Profile 146
RBX-7455 - Drug Profile 148
ridinilazole - Drug Profile 149
SER-109 - Drug Profile 151
SER-262 - Drug Profile 152
Small Molecule to Inhibit Guanine Riboswitches for MRSA and Clostridium Difficile Infections - Drug Profile 153
Small Molecules for Clostridium Difficile Infections - Drug Profile 154
Small Molecules for Clostridium Difficile Infections - Drug Profile 155
Small Molecules to Inhibit CD Toxin A and Toxin B for Clostridium Difficile Infections - Drug Profile 156
Small Molecules to Inhibit DNA Synthesis for Infectious Diseases - Drug Profile 157
Small Molecules to Inhibit Dynamin for Clostridium Difficile Infections - Drug Profile 159
SQ-641 - Drug Profile 160
SYN-004 - Drug Profile 161
SYN-006 - Drug Profile 163
VAL-301 - Drug Profile 164
VLA-84 - Drug Profile 166
VP-20621 - Drug Profile 168
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Recent Pipeline Updates 169
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Dormant Projects 198
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Discontinued Products 200
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Product Development Milestones 201
Featured News & Press Releases 201
Appendix 209
Methodology 209
Coverage 209
Secondary Research 209
Primary Research 209
Expert Panel Validation 209
Contact Us 209
Disclaimer 210
List of Tables
Number of Products under Development for Clostridium difficile Infections (Clostridium difficile Associated Disease), H1 2016 16
Number of Products under Development for Clostridium difficile Infections (Clostridium difficile Associated Disease) - Comparative Analysis, H1 2016 17
Number of Products under Development by Companies, H1 2016 18
Number of Products under Development by Companies, H1 2016 (Contd..1) 19
Number of Products under Development by Companies, H1 2016 (Contd..2) 20
Number of Products under Investigation by Universities/Institutes, H1 2016 21
Comparative Analysis by Late Stage Development, H1 2016 22
Comparative Analysis by Clinical Stage Development, H1 2016 23
Comparative Analysis by Early Stage Development, H1 2016 24
Comparative Analysis by Unknown Stage Development, H1 2016 25
Products under Development by Companies, H1 2016 26
Products under Development by Companies, H1 2016 (Contd..1) 27
Products under Development by Companies, H1 2016 (Contd..2) 28
Products under Development by Companies, H1 2016 (Contd..3) 29
Products under Investigation by Universities/Institutes, H1 2016 30
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Absynth Biologics Limited, H1 2016 31
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Actelion Ltd, H1 2016 32
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Adenium Biotech ApS, H1 2016 33
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by AIMM Therapeutics B.V., H1 2016 34
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by AmpliPhi Biosciences Corporation, H1 2016 35
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Angothera GmbH, H1 2016 36
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Appili Therapeutics, H1 2016 37
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Assembly Biosciences, Inc., H1 2016 38
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by AvidBiotics Corp., H1 2016 39
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by C3 Jian, Inc, H1 2016 40
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Da Volterra, H1 2016 41
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Daiichi Sankyo Company, Limited, H1 2016 42
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by e-Therapeutics Plc, H1 2016 43
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Evec, Inc., H1 2016 44
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by GangaGen Inc., H1 2016 45
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by ImmunoBiology Limited, H1 2016 46
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Immuron Limited, H1 2016 47
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Inovio Pharmaceuticals, Inc., H1 2016 48
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Integrated BioTherapeutics, Inc., H1 2016 49
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by MedImmune, LLC, H1 2016 50
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Merck & Co., Inc., H1 2016 51
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by MGB Biopharma Limited, H1 2016 52
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Microbiotix, Inc., H1 2016 53
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Micropharm Limited, H1 2016 54
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Morphochem AG, H1 2016 55
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Nanotherapeutics, Inc., H1 2016 56
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Novabiotics Limited, H1 2016 57
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by NovoBiotic Pharmaceuticals, LLC, H1 2016 58
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Oragenics, Inc., H1 2016 59
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Otsuka Holdings Co., Ltd., H1 2016 60
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Pfizer Inc., H1 2016 61
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Procarta Biosystems Limited, H1 2016 62
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Prokarium Limited, H1 2016 63
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Rebiotix Inc., H1 2016 64
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Sanofi Pasteur SA, H1 2016 65
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Seres Therapeutics, Inc., H1 2016 66
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Shire Plc, H1 2016 67
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Sorrento Therapeutics, Inc., H1 2016 68
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Stellar Biotechnologies, Inc., H1 2016 69
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Summit Therapeutics Plc, H1 2016 70
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Synthetic Biologics, Inc., H1 2016 71
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Valevia UK Limited, H1 2016 72
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Valneva SE, H1 2016 73
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by VaxInnate Corporation, H1 2016 74
Assessment by Monotherapy Products, H1 2016 75
Assessment by Combination Products, H1 2016 76
Number of Products by Stage and Target, H1 2016 78
Number of Products by Stage and Mechanism of Action, H1 2016 80
Number of Products by Stage and Route of Administration, H1 2016 82
Number of Products by Stage and Molecule Type, H1 2016 84
Clostridium difficile Infections (Clostridium difficile Associated Disease) Therapeutics - Recent Pipeline Updates, H1 2016 174
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Dormant Projects, H1 2016 203
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Dormant Projects (Contd..1), H1 2016 204
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Discontinued Products, H1 2016 205
List of Figures
Number of Products under Development for Clostridium difficile Infections (Clostridium difficile Associated Disease), H1 2016 16
Number of Products under Development for Clostridium difficile Infections (Clostridium difficile Associated Disease) - Comparative Analysis, H1 2016 17
Number of Products under Development by Companies, H1 2016 18
Number of Products under Investigation by Universities/Institutes, H1 2016 21
Comparative Analysis by Late Stage Development, H1 2016 22
Comparative Analysis by Clinical Stage Development, H1 2016 23
Comparative Analysis by Early Stage Products, H1 2016 24
Assessment by Monotherapy Products, H1 2016 75
Assessment by Combination Products, H1 2016 76
Number of Products by Top 10 Targets, H1 2016 77
Number of Products by Stage and Top 10 Targets, H1 2016 77
Number of Products by Top 10 Mechanism of Actions, H1 2016 79
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 79
Number of Products by Routes of Administration, H1 2016 81
Number of Products by Stage and Routes of Administration, H1 2016 81
Number of Products by Top 10 Molecule Types, H1 2016 83
Number of Products by Stage and Top 10 Molecule Types, H1 2016 83
